Chimeric tumor suppressor 1, a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand.

Adenoviral chimeric tumor suppressor 1 (CTS1) gene transfer was evaluated as a novel approach of somatic gene therapy for malignant glioma. CTS1 is an artificial p53-based gene designed to resist various pathways of p53 inactivation. Here, we report that an adenovirus encoding CTS1 (Ad-CTS1) induces growth arrest and loss of viability in all glioma cell lines examined, in the absence of specific cell cycle changes. In contrast, an adenovirus encoding wild-type p53 (Ad-p53) does not consistently induce apoptosis in the same cell lines. Electron microscopic analysis of Ad-CTS1-infected glioma cells reveals complex cytoplasmic pathology and delayed apoptotic changes. Ad-CTS1 induces prominent activation of various p53 target genes, including p21 and MDM-2, but has no relevant effects on BCL-2 family protein expression. Although Ad-CTS1 strongly enhances CD95 expression at the cell surface, endogenous CD95/CD95 ligand interactions do not mediate CTS1-induced cell death. This is because Ad-CTS1 promotes neither caspase activation nor mitochondrial cytochrome c release and because the caspase inhibitors, z-val-Ala-DL-Asp-fluoromethylketone (zVAD)-fmk or z-Ile-Glu-Thr-Asp- fluoromethylketone (z-IETD)-fmk, do not block CTS1-induced cell death. Ad-CTS1 synergizes with radiotherapy and CD95 ligand in killing glioma cells. In summary, Ad-CTS1 induces an unusual type of cell death that appears to be independent of BCL-2 family proteins, cytochrome c release, and caspases. CTS1 gene transfer is a promising strategy of somatic gene therapy for malignant glioma.

[1]  J. Dichgans,et al.  CD95 Ligand: Lethal Weapon Against Malignant Glioma? , 1998, Brain pathology.

[2]  G. Fulci,et al.  p53 and Brain Tumors: From Gene Mutations to Gene Therapy , 1998, Brain pathology.

[3]  A. Merlo,et al.  Frequent Co‐Alterations of TP53, p16/CDKN2A, p14ARF, PTEN Tumor Suppressor Genes in Human Glioma Cell Lines. , 1999, Brain pathology.

[4]  B. Badie,et al.  Adenovirus-mediated p53 gene delivery inhibits 9L glioma growth in rats. , 1995, Neurological research.

[5]  S. Kügler,et al.  Transduction of axotomized retinal ganglion cells by adenoviral vector administration at the optic nerve stump: an in vivo model system for the inhibition of neuronal apoptotic cell death , 1999, Gene Therapy.

[6]  J. Dichgans,et al.  Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. , 1999, Biochemical and biophysical research communications.

[7]  H. Lassmann,et al.  Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials , 1999, Nature Medicine.

[8]  M. Weller,et al.  Death ligand/receptor-independent caspase activation mediates drug-induced cytotoxic cell death in human malignant glioma cells , 1999, Oncogene.

[9]  T. McDonnell,et al.  Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. , 1997, Journal of the National Cancer Institute.

[10]  F. Lacroix,et al.  Cancer gene therapy mediated by CTS1, a p53 derivative: Advantage over wild-type p53 in growth inhibition of human tumors overexpressing MDM2 , 2000, Cancer Gene Therapy.

[11]  W. Yung,et al.  Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. , 1996, Cancer research.

[12]  Yusuke Nakamura,et al.  p53AIP1, a Potential Mediator of p53-Dependent Apoptosis, and Its Regulation by Ser-46-Phosphorylated p53 , 2000, Cell.

[13]  T. Taniguchi,et al.  Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. , 2000, Science.

[14]  S. Walter,et al.  Transfection of a vector expressing wild-type p53 into cells of two human glioma cell lines enhances radiation toxicity. , 1998, Radiation research.

[15]  M. Weller,et al.  Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage. , 2001, European journal of pharmacology.

[16]  J. Dichgans,et al.  Predicting chemoresistance in human malignant glioma cells: The role of molecular genetic analyses , 1998, International journal of cancer.

[17]  J. Dichgans,et al.  Sensitization to CD95 ligand-induced apoptosis in human glioma cells by hyperthermia involves enhanced cytochrome c release , 2000, Oncogene.

[18]  M. Weller,et al.  Dexamethasone-mediated protection from drug cytotoxicity: association with p21WAF1/CIP1 protein accumulation? , 1998, Oncogene.

[19]  K. Kinzler,et al.  A model for p53-induced apoptosis , 1997, Nature.

[20]  Z. Ram,et al.  Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells , 1997, Nature Medicine.

[21]  John Calvin Reed,et al.  Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. , 1994, Oncogene.

[22]  B. Kachar,et al.  Structural elements common to mitosis and apoptosis. , 1999, Tissue & cell.

[23]  M. Weller,et al.  Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. , 1994, The Journal of clinical investigation.

[24]  M. Weller,et al.  Local Fas/APO‐1 (CD95) ligand‐mediated tumor cell killing in vivo , 1995, European journal of immunology.

[25]  V. Heidecke,et al.  Immune response induced by retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiforme , 2000, Gene Therapy.

[26]  M. Weller,et al.  p53 Enhances BAK and CD95 Expression in Human Malignant Glioma Cells but Does Not Enhance CD95L-Induced Apoptosis , 1999, Cellular Physiology and Biochemistry.

[27]  J. E. Celis,et al.  Cell Biology: A Laboratory Handbook , 1997 .

[28]  F. Khuri,et al.  Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. , 1999, Journal of the National Cancer Institute.

[29]  C. Goh,et al.  Combined radiation and p53 gene therapy of malignant glioma cells , 1999, Cancer Gene Therapy.

[30]  S. Lowe,et al.  PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. , 2000, Genes & development.

[31]  Hanns Lochmüller,et al.  Adenovirus‐mediated Wild‐type p53 Gene Transfer and Overexpression Induces Apoptosis of Human Glioma Cells Independent of Endogenous p53 Status , 1997, Journal of neuropathology and experimental neurology.

[32]  P S Lin,et al.  Enhanced radiosensitivity of malignant glioma cells after adenoviral p53 transduction. , 1999, Journal of neurosurgery.

[33]  L. Bracco,et al.  CTS1: a p53-derived chimeric tumor suppressor gene with enhanced in vitro apoptotic properties. , 1998, The Journal of clinical investigation.

[34]  J. Schulz,et al.  Crm-A, bcl-2 and NDGA inhibit CD95L-induced apoptosis of malignant glioma cells at the level of caspase 8 processing , 1998, Cell Death and Differentiation.

[35]  D. Klatzmann,et al.  A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. , 1998, Human gene therapy.

[36]  D. Klatzmann,et al.  A Phase I/II Study of Herpes Simplex Virus Type 1 Thymidine Kinase "Suicide" Gene Therapy for Recurrent Glioblastoma , 1998 .

[37]  W. Cavenee,et al.  Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. , 2000, Cancer research.